[go: up one dir, main page]

WO1991006293A3 - Procede et composition servant a arreter de façon reversible l'activite d'un muscle - Google Patents

Procede et composition servant a arreter de façon reversible l'activite d'un muscle Download PDF

Info

Publication number
WO1991006293A3
WO1991006293A3 PCT/US1990/006241 US9006241W WO9106293A3 WO 1991006293 A3 WO1991006293 A3 WO 1991006293A3 US 9006241 W US9006241 W US 9006241W WO 9106293 A3 WO9106293 A3 WO 9106293A3
Authority
WO
WIPO (PCT)
Prior art keywords
arresting
reversibly
muscle activity
composition containing
butanedione monoxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/006241
Other languages
English (en)
Other versions
WO1991006293A2 (fr
Inventor
Louis A Mulieri
Gerd Hasenfuss
Norman R Alpert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Original Assignee
University of Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont filed Critical University of Vermont
Publication of WO1991006293A2 publication Critical patent/WO1991006293A2/fr
Publication of WO1991006293A3 publication Critical patent/WO1991006293A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Le procédé décrit, qui sert à arrêter de façon réversible l'activité d'un muscle (par exemple pour obtenir une cardioplégie), consiste à administrer un réactif, tel que du monoxime de 2,3-butanedione, qui bloque de façon sélective et réversible l'interaction des protéines contractiles actine et myosine. Des compositions servant à arrêter l'activité d'un muscle sont également décrites.
PCT/US1990/006241 1989-11-01 1990-11-01 Procede et composition servant a arreter de façon reversible l'activite d'un muscle Ceased WO1991006293A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43061489A 1989-11-01 1989-11-01
US430,614 1989-11-01

Publications (2)

Publication Number Publication Date
WO1991006293A2 WO1991006293A2 (fr) 1991-05-16
WO1991006293A3 true WO1991006293A3 (fr) 1991-06-13

Family

ID=23708314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006241 Ceased WO1991006293A2 (fr) 1989-11-01 1990-11-01 Procede et composition servant a arreter de façon reversible l'activite d'un muscle

Country Status (1)

Country Link
WO (1) WO1991006293A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723818B1 (fr) * 1994-08-25 1999-03-05 Implants & Instr Chirurg Composition de perfusion pour ameliorer la conservation d'organes vivants
AU4990599A (en) * 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AM. J. PHYSIOL., Vol. 255, No. 1, part 2, 1988, THE AMERICAN PHYSIOLOGICAL SOCIETY, W.G. NAYLER et al., "The Stunned Myo-Cardium: Effect of Electrical and Mechanical Arrest and Osmolarity", pages H60-H69. *
BIOPHYSICAL JOURNAL, Vol. 47, No. 2, part 2, T-Pos197, February 1985, The Rockefeller University Press, T.B. WARREN et al., "Effects of 2,3-Butanedione Monoxime (BDM) on Force Production and Myosin Light Chain Phosphorylation (MYLCP) in Mammalian Smooth and Skeletal Muscle"; & 29TH ANN. MEET. BIOPHYS. SOC., Baltimore, 24-28 Feb 1985, see page 295a. *
CHEMICAL ABSTRACTS, Vol. 102, No. 23, abstract 199072c, 10 June 1985, (Columbus, Ohio, US), T. LI et al., "Effects of Diacetyl Monoxime on Cardiac Excitation-Contraction Coupling"; & J. PHARMACOL. EXP. THER. 1985, 232(3), 688-95, see page 173. *
CHEMICAL ABSTRACTS, Vol. 108, No. 13, 106325y, 28 March 1988, (Columbus, Ohio, US), M.W. FRYER et al., "Paralysis of Skeletal Muscle by Butanedione Monoxime, a Chemical Phosphatase"; & PFLUEGERS ARCH. 1988, 411(1), 76-9, see page 53. *
CHEMICAL ABSTRACTS, Vol. 109, No. 23, 208977a, 5 December 1988, (Columbus, Ohio, US), C.S. PACKER et al., "The Effect of 2,3-Butanedione Monoxime (BDM) in Smooth Muscle Mechanical Properties"; & PFLUEGERS ARCH. 1988, 412(6), 659-64, see page 471. *
CIRC. RES., Vol. 65, No. 5, November 1989, L.A. MULIERI et al., "Protection of Human Left Ventricular Myocardium from Cutting Injury with 2,3-Butanedione Monoxime", pages 1441-1444. *
DIALOG INFORMATION SERVICES FILE 155, (Medline), Accession No. 02957493, J.R. WILLIAMSON et al., "Contribution of Tissue Acidosis to Ischemic Injury in the Perfused Rat Heart"; & CIRCULATION, Mar. 1976, 53(3 Suppl. 1), p. 3-14. *
DIALOG INFORMATION SERVICES FILE 155, (Medline), Accession No. 04841582, PH SUGDEN et al., "The Effect of Glucose, Acatate, Lactate and Insulin on Protein Degradation in the Perfused Rat Heart"; & BIOCHEM J, 15 Sep. 1982, 206(3), p. 467-72. *
LABORATORY INVESTIGATION, Vol. 58, No. 6, 1988, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY INC, (US), J.S. ELZ et al., "Contractile Activity and Reperfusion-Induced Calcium Gain After Ischemia in the Isolated Rat Heart", pages 653-659. *
PFLUEGERS ARCH., Vol. 416, No. 1-2, April 1990, SPRINGER-VERLAG, E.M. BLANCHARD et al., "The Effect of 2,3-Butanedione Monoxime on Initial Beat, Tension, and Aequorin Light Output of Ferret Papillary Muscles", pages 219-221. *
THE AMERICAN JOURNAL OF CARDIOLOGY, Vol. 63, No. 10, 7 March 1989, J.S. ELZ et al., "Reperfusion-Induced Calcium Gain After Ischemia", pages 7E-13E. *

Also Published As

Publication number Publication date
WO1991006293A2 (fr) 1991-05-16

Similar Documents

Publication Publication Date Title
MY103850A (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them.
IE812075L (en) Composition
HK12184A (en) Substituted ortho-anisamides, methods of preparing them, compositions containing them and their application as psychotropic agents
IL75586A0 (en) Pharmaceutical compositions containing indole-2-alkanoic acids and derivatives thereof,and certain such novel compounds
AU2091588A (en) New imidazolidines substituted by a hydroxymethyl radical and a substituted phenyl radical, the process for their preparation, their use as medicaments, the pharmaceutical compositions containing them and an intermediate for their preparation
PT79840B (en) Process for the preparation of polipeptides with alpha-amilase inhibiting action and pharmaceutical compositions therewith
HUT39971A (en) Pesticide compositions containing 3,5-diaryl-1,2,4-triazole derivatives as active ingredients and process for preparing the active substances
IE882594L (en) Water-hardening polymer preparation
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
IL74293A (en) 1,4-disubstituted- 2,6,7 - trioxabicyclo (2.2.2) octane derivatives, their preparation and pesticidal compositions containing them
ES8505230A1 (es) &#34;un procedimiento para la preparacion de composiciones insecticidas&#34;.
DE2861081D1 (en) 2,5,7-trimethyloctane-3-ol and 2,4-dimethylnonane-8-ol; processes for their preparation; their use as olfactory agents; olfactory compositions containing them, as well as the preparation of such olfactory compositions
IE801149L (en) Trihydroxy-piperidines
MX9203140A (es) Derivados de 4 fenil-4(n-(fenil)amido)-piperidina y las composiciones farmaceuticas, asi como el metodo aplicado para tales compuestos.
WO1991006293A3 (fr) Procede et composition servant a arreter de façon reversible l&#39;activite d&#39;un muscle
IE781659L (en) Pseudotrisaccharides
DE3562221D1 (en) Fibre mixture for reinforcing materials such as hydraulic binders, use of this mixture and formed objects obtained by using this mixture
EP0339878A3 (fr) Dérivés de la propanamine
IL82145A0 (en) Substituted thiacycloalkeno(3,2-b)pyridines,their preparation and pharmaceutical compositions containing them
IL76327A0 (en) Phenylacetonitrile derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
IL74264A (en) Preparation of calciferol derivatives,certain such novel compounds and pharmaceutical compositions containing them
HUT40648A (en) Process for producing optically active substituted 1,4-dihydro-pyridines and pharmaceutical compositions containing them as active agents
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
PT72365A (en) Process for the preparation of a pesticidal composition containing n,n-dimethyl-o-(4,6-dihydro-2h-thien/3,4-c/pyrazol-3-yl)-carbamates as well as their 5-oxides and 5,5-dioxides
EP0348664A3 (fr) Compositions pharmaceutiques contenant des monoacétoacétines pour le traitement des tumeurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWW Wipo information: withdrawn in national office

Ref document number: 1991900521

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1991900521

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
NENP Non-entry into the national phase

Ref country code: CA